MAMTA VIJAYVARGIYA
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology ORANGE CITY, FL NPI 1598733685
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology FL Karyopharm Therapeutics Inc. All categories
General Payments — all program years on this page
$18,355.00
- Category: General Payments
- Program years: PY2018–2024
- Record count: 531
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $6,531.46 across 61 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $5,065.00 | 6 |
| Food and Beverage | $1,166.67 | 54 |
| Travel and Lodging | $299.79 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Karyopharm Therapeutics Inc. | $2,754.79 | 3 |
| Acerta Pharma LLC | $2,079.37 | 8 |
| BeiGene USA, Inc. | $729.51 | 5 |
| PFIZER INC. | $152.35 | 9 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $135.46 | 6 |
| Gilead Sciences, Inc. | $74.19 | 3 |
| Celgene Corporation | $70.96 | 3 |
| GlaxoSmithKline, LLC. | $62.41 | 3 |
| Incyte Corporation | $58.04 | 3 |
| GENZYME CORPORATION | $54.38 | 2 |
| Janssen Biotech, Inc. | $44.01 | 2 |
| Exelixis Inc. | $41.52 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $40.45 | 2 |
| ABBVIE INC. | $34.49 | 1 |
| TAIHO ONCOLOGY, INC. | $27.08 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $26.08 | 1 |
| Stemline Therapeutics Inc. | $24.35 | 1 |
| Merck Sharp & Dohme Corporation | $23.47 | 1 |
| Daiichi Sankyo Inc. | $23.03 | 1 |
| Genentech USA, Inc. | $22.99 | 1 |
| JAZZ PHARMACEUTICALS INC. | $20.27 | 1 |
| Mirati Therapeutics, Inc. | $17.86 | 1 |
| EMD Serono, Inc. | $14.40 | 1 |
By program year
Records — PY2024 (61)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.